Hormonal treatment of endometrial carcinoma.
Endometrial cancer has typically been regarded as a relatively benign disease. However, survival rates for patients with advanced-stage or recurrent disease are very poor and more adequate systemic treatment is certainly needed. Being a tumor that arises from a hormone responsive tissue, endometrial cancer is a logical target for endocrine manipulation. This article gives an overview of our current knowledge on hormonal therapy and highlights the large potential for improvement in results of such therapy. Target areas for future research are described.
Dept. Gynecologic Oncology, Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway. mark.baekelandt@klinmed.uio.no
Mark
M
Baekelandt
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy
D018931:Antineoplastic Agents, Hormonal